Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers

被引:1
作者
Picton, Anabela C. P. [1 ]
Paximadis, Maria [1 ,2 ]
Koor, Gemma W. [1 ,2 ]
Bharuthram, Avani [1 ,2 ]
Shalekoff, Sharon [1 ,2 ]
Lassauniere, Ria [3 ]
Ive, Prudence [2 ,4 ]
Tiemessen, Caroline T. [1 ,2 ]
机构
[1] Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa
[2] Univ Witwatersrand, Sch Pathol, Dept Virol, Fac Hlth Sci, Johannesburg, South Africa
[3] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Virus Res & Dev Lab, Copenhagen, Denmark
[4] Univ Witwatersrand, Sch Clin Med, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
HIV-1; control; CCR5; expression; immune activation; ligands; IL-10; IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTE ACTIVATION; SERUM CHEMOKINE LEVELS; BETA-CHEMOKINES; DISEASE PROGRESSION; PLASMA-LEVELS; CELL SUBSETS; SOLUBLE CD14; INFECTION; SUSCEPTIBILITY;
D O I
10.3389/fimmu.2021.781263
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Unique Individuals who exhibit either suppressive HIV-1 control, or the ability to maintain low viral load set-points and preserve their CD4+ T cell counts for extended time periods in the absence of antiretroviral therapy, are broadly termed HIV-1 controllers. We assessed the extent to which black South African controllers (n=9), differ from uninfected healthy controls (HCs, n=22) in terms of lymphocyte and monocyte CCR5 expression (density and frequency of CCR5-expressing cells), immune activation as well as peripheral blood mononuclear cell (PBMC) mitogen-induced chemokine/cytokine production. In addition, relative CD4+ T cell CCR5 mRNA expression was assessed in a larger group of controllers (n=20) compared to HCs (n=10) and HIV-1 progressors (n=12). Despite controllers having significantly higher frequencies of activated CD4+ and CD8+ T cells (HLA-DR+) compared to HCs, CCR5 density was significantly lower in these T cell populations (P=0.039 and P=0.064, respectively). This lower CCR5 density was largely attributable to controllers with higher VLs (>400 RNA copies/ml). Significantly lower CD4+ T cell CCR5 density in controllers was maintained (P=0.036) when HCs (n=12) and controllers (n=9) were matched for age. CD4+ T cell CCR5 mRNA expression was significantly less in controllers compared to HCs (P=0.007) and progressors (P=0.002), whereas HCs and progressors were similar (P=0.223). The levels of soluble CD14 in plasma did not differ between controllers and HCs, suggesting no demonstrable monocyte activation. While controllers had lower monocyte CCR5 density compared to the HCs (P=0.02), significance was lost when groups were age-matched (P=0.804). However, when groups were matched for both CCR5 promoter haplotype and age (n=6 for both) reduced CCR5 density on monocytes in controllers relative to HCs was highly significant (P=0.009). Phytohemagglutinin-stimulated PBMCs from the controllers produced significantly less CCL3 (P=0.029), CCL4 (P=0.008) and IL-10 (P=0.028) compared to the HCs, which was largely attributable to the controllers with lower VLs (<400 RNA copies/ml). Our findings support a hypothesis of an inherent (genetic) predisposition to lower CCR5 expression in individuals who naturally control HIV-1, as has been suggested for Caucasian controllers, and thus, likely involves a mechanism shared between ethnically divergent population groups.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Association Between HIV-1 Tropism and CCR5 Human Haplotype E in a Caucasian Population
    Huik, Kristi
    Avi, Radko
    Uibopuu, Helen
    Pauskar, Merit
    Margus, Tonu
    Karki, Tonis
    Krispin, Tonu
    Kool, Piret
    Rueuetel, Kristi
    Talu, Ave
    Abel-Ollo, Katri
    Uuskuela, Anneli
    Carrillo, Andrew
    He, Weijing
    Ahuja, Sunil K.
    Lutsar, Irja
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (03) : 239 - 244
  • [32] Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection
    Caldwell, David J.
    Evans, Jeffery D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (18) : 3231 - 3242
  • [33] Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments
    Imai, Masaki
    Baranyi, Lajos
    Okada, Noriko
    Okada, Hidechika
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 353 (04) : 851 - 856
  • [34] The chemokine receptor CCR5: multi-faceted hook for HIV-1
    Natacha Faivre
    Christel Verollet
    Fabrice Dumas
    Retrovirology, 21
  • [35] CCR5 Expression Is Reduced in Lymph Nodes of HIV Type 1-Infected Women, Compared With Men, But Does Not Mediate Sex-Based Differences in Viral Loads
    Meditz, Amie L.
    Folkvord, Joy M.
    Lyle, Ngan H.
    Searls, Kristina
    Lie, Yolanda S.
    Coakley, Eoin P.
    McCarter, Martin
    MaWhinney, Samantha
    Connick, Elizabeth
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (06) : 922 - 930
  • [36] Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians
    Kaur, Gurvinder
    Singh, P.
    Rapthap, C. C.
    Kumar, N.
    Vajpayee, M.
    Sharma, S. K.
    Wanchu, A.
    Mehra, N. K.
    HUMAN IMMUNOLOGY, 2007, 68 (05) : 454 - 461
  • [37] The chemokine receptor CCR5: multi-faceted hook for HIV-1
    Faivre, Natacha
    Verollet, Christel
    Dumas, Fabrice
    RETROVIROLOGY, 2024, 21 (01)
  • [38] CCR5 promoter polymorphisms and HIV-1 perinatal transmission in Brazilian children
    de Souza, PR
    Arraes, LC
    de Lima, JL
    Bruneska, D
    Milanese, M
    Crovella, S
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2006, 69 (01) : 77 - 84
  • [39] Global stability of a HIV-1 CCR5 gene therapy with suicide gene
    Liu, Junmei
    Ma, Yonggang
    SYSTEMS SCIENCE & CONTROL ENGINEERING, 2024, 12 (01)
  • [40] HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
    Pugach, Pavel
    Marozsan, Andre J.
    Ketas, Thomas J.
    Landes, Elissa L.
    Moore, John P.
    Kuhmann, Shawn E.
    VIROLOGY, 2007, 361 (01) : 212 - 228